Summary: Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but
Summary: Novavax’ Q3 earnings are due on 6th November. The vaccine developer was part of
Summary: Novavax’s financial position improved significantly with a $570 million cash infusion from Sanofi, boosting
Summary: Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential
Summary: Novavax reported Q2 earnings with a miss on EPS and revenue, causing a drop
Summary: Novavax’s Q1 2024 earnings were so-so, but a major partnership with Sanofi sent its
Summary: Novavax, Inc. secured a lucrative deal with Sanofi, receiving potentially $1.2 billion in cash
Summary: Novavax has seen a surge in stock price due to recent COVID-19 and bird
Summary: Novavax announced Q1 2024 results with a beat on EPS and a miss on
Summary: Novavax, Inc.’s Sanofi partnership provides much-needed financial support via upfront and milestone payments, stabilizing